| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Adelaide Greco | Q57613439 |
| Luigi Auletta | Q61856348 | ||
| Luca Basso | Q89659156 | ||
| Marco Salvatore | Q37370172 | ||
| P2093 | author name string | M Mancini | |
| M Salvatore | |||
| L Meomartino | |||
| G Fatone | |||
| M F Fiordelisi | |||
| P2860 | cites work | Diffusion MRI of cancer: From low to high b-values | Q57471575 |
| A multi-parametric PET/MRI study of breast cancer: Evaluation of DCE-MRI pharmacokinetic models and correlation with diffusion and functional parameters | Q58090438 | ||
| The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies | Q64030468 | ||
| Transgenic Animal Models to Visualize Cancer-Related Cellular Processes by Bioluminescence Imaging | Q64086979 | ||
| Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations | Q73080379 | ||
| High b-value diffusion-weighted MRI of normal brain | Q74266217 | ||
| Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer | Q83405058 | ||
| Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology | Q83472523 | ||
| Precision medicine--personalized, problematic, and promising | Q85219362 | ||
| DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report | Q90972307 | ||
| State-of-the-Art Preclinical Photoacoustic Imaging in Oncology: Recent Advances in Cancer Theranostics | Q92643865 | ||
| Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient | Q22121929 | ||
| A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro | Q24647698 | ||
| Probing physiology and molecular function using optical imaging: applications to breast cancer | Q24801154 | ||
| The Expanding Toolbox of In Vivo Bioluminescent Imaging | Q26742117 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Diffusion weighted magnetic resonance imaging and its recent trend-a survey | Q28084561 | ||
| Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging | Q28478679 | ||
| Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR) | Q28732809 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Molecular imaging of the tumor microenvironment for precision medicine and theranostics. | Q30367515 | ||
| Ultrasound molecular imaging: Moving toward clinical translation | Q30375187 | ||
| Photoacoustic tomography: principles and advances | Q30420071 | ||
| US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice | Q30431243 | ||
| Molecular ultrasound imaging: current status and future directions | Q30474725 | ||
| Foundations of advanced magnetic resonance imaging | Q30499144 | ||
| The physics of functional magnetic resonance imaging (fMRI). | Q30665074 | ||
| High frequency ultrasound: a new frontier for ultrasound | Q30957340 | ||
| A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues | Q31993838 | ||
| Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. | Q33215142 | ||
| In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice | Q33272403 | ||
| Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy | Q33353929 | ||
| Radiogenomic Analysis of Oncological Data: A Technical Survey | Q33624662 | ||
| Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer | Q33641143 | ||
| Breast MR with special focus on DW-MRI and DCE-MRI | Q33965703 | ||
| Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study. | Q33997699 | ||
| A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer | Q34192568 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| Ultrasound imaging: principles and applications in rodent research | Q34282862 | ||
| Noninvasive imaging of quantum dots in mice | Q34291094 | ||
| Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. | Q34482105 | ||
| Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging | Q34591102 | ||
| Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts | Q35028823 | ||
| Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts | Q35031049 | ||
| Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging | Q35050714 | ||
| Molecular imaging in living subjects: seeing fundamental biological processes in a new light | Q35082602 | ||
| Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model | Q35784634 | ||
| Harnessing the Power of Molecular Imaging for Precision Medicine | Q36535236 | ||
| Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 | ||
| [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography | Q36627997 | ||
| How molecular imaging is speeding up antiangiogenic drug development | Q36661253 | ||
| Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model. | Q36699083 | ||
| Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine | Q36778929 | ||
| Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model | Q37050403 | ||
| Diffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applications. | Q37087591 | ||
| Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). | Q37301288 | ||
| Definition and application of precision medicine. | Q37346600 | ||
| Small animal imaging facility: new perspectives for the radiologist | Q37350714 | ||
| Nanomedicine: perspective and promises with ligand-directed molecular imaging | Q37408545 | ||
| Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules | Q37453801 | ||
| Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells | Q37456176 | ||
| Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response? | Q37600890 | ||
| Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer | Q37641611 | ||
| Near-infrared quantum dots for HER2 localization and imaging of cancer cells | Q37641853 | ||
| Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study | Q37694797 | ||
| Breast cancer, version 3.2013: featured updates to the NCCN guidelines | Q37709567 | ||
| Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics | Q37990912 | ||
| Preclinical molecular imaging using PET and MRI. | Q38062421 | ||
| Preclinical imaging: an essential ally in modern biosciences. | Q38154514 | ||
| Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging | Q38205006 | ||
| Imaging preclinical tumour models: improving translational power | Q38221430 | ||
| Models and methods for analyzing DCE-MRI: a review. | Q38282639 | ||
| Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors | Q38380533 | ||
| Physical principles of magnetic resonance imaging | Q38657840 | ||
| Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine | Q38719044 | ||
| Fundamentals of Pharmacogenetics in Personalized, Precision Medicine | Q38924921 | ||
| Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts. | Q39298731 | ||
| Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model | Q39381175 | ||
| Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment | Q39441415 | ||
| Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model | Q39979176 | ||
| Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature | Q40187867 | ||
| High Frequency Ultrasonic Imaging | Q40324258 | ||
| 18-FDG imaging in breast cancer | Q40824121 | ||
| Image reconstruction in optical tomography. | Q40838834 | ||
| A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel | Q41140406 | ||
| Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer. | Q41173608 | ||
| Visualization of GFP-expressing tumors and metastasis in vivo | Q42828961 | ||
| PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study | Q44780804 | ||
| Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study | Q46790235 | ||
| Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. | Q46872269 | ||
| 18F-Fluoromisonidazole in tumor hypoxia imaging | Q47135488 | ||
| The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). | Q47283269 | ||
| Semi-parametric arterial input functions for quantitative dynamic contrast enhanced magnetic resonance imaging in mice | Q47414003 | ||
| NCCN Guidelines Insights: Breast Cancer, Version 1.2017. | Q47579286 | ||
| DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer. | Q47670339 | ||
| Clinical Breast Magnetic Resonance Imaging: Technique, Indications, and Future Applications | Q47742442 | ||
| Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer | Q49475238 | ||
| Role of semi-quantitative dynamic contrast-enhanced MR imaging in characterization and grading of prostate cancer. | Q50528267 | ||
| Fluorescence molecular tomography enables in vivo visualization and quantification of nonunion fracture repair induced by genetically engineered mesenchymal stem cells. | Q50870395 | ||
| Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel. | Q50870880 | ||
| Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts. | Q50888215 | ||
| A Modified Tri-Exponential Model for Multi-b-value Diffusion-Weighted Imaging: A Method to Detect the Strictly Diffusion-Limited Compartment in Brain. | Q52657218 | ||
| [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. | Q53194822 | ||
| [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. | Q55286904 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | precision medicine | Q17075943 |
| xenograft model antitumor assay | Q73347741 | ||
| breast neoplasm | Q23929670 | ||
| P304 | page(s) | 8946729 | |
| P577 | publication date | 2019-09-22 | |
| P1433 | published in | Contrast Media & Molecular Imaging | Q2995750 |
| P1476 | title | Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models | |
| P478 | volume | 2019 |
Search more.